Untersuchung zur Korrelation von HLA-DR-Expression, Procalcitonin und Interleukin 6 mit dem Krankheitsverlauf sowie ihrer Eignung zur Risikostratifizierung bei Patienten mit Sepsis

Diese Studie untersuchte an 111 Patienten mit Sepsis den Zusammenhang der zeitlichen Kinetik von Interleukin 6, Procalcitonin und der HLA-DR-Expression auf Monozyten mit dem Krankheitsverlauf sowie ihre Eignung zu einer frühen Risikostratifizierung. Es zeigte sich in den aufgestellten logistischen R...

Ausführliche Beschreibung

Gespeichert in:
1. Verfasser: Schumann, Florian
Beteiligte: Max, M. (PD Dr.) (BetreuerIn (Doktorarbeit))
Format: Dissertation
Sprache:Deutsch
Veröffentlicht: Philipps-Universität Marburg 2011
Klinik für Anästhesie und Intensivtherapie
Ausgabe:http://dx.doi.org/10.17192/z2011.0548
Schlagworte:
Online Zugang:PDF-Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

1. Meisner M, Tschaikowsky K, Palmaers T, Schmidt J. Comparison of procalci- tonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit Care (Lond). 1999: 3: 45-50.


2. Presterl E, Staudinger T, Pettermann M, Lassnigg A, Burgmann H, Winkler S, Frass M, Graninger W. Cytokine profile and correlation to the APACHE III and MPM II scores in patients with sepsis. Am J Respir Crit Care Med. 1997: 156: 825-32.


3. Angus, D. C., Linde-Zwirble, W. T., Lidicker, J., Clermont, G., Carcillo, J., and Pinsky, M. R. Epidemiology of severe sepsis in the United States: analysis of in- cidence, outcome and associated costs of care. Critical Care Medicine 29, 1303- 1310. 2001. Ref Type: Journal (Full)


4. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Na- ture 1998: 392: 245-52.


5. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult- population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med. 2004: 30: 589-96.


6. Vincent JL. Dear SIRS, I'm sorry to say that I don't like you.. Crit Care Med. 1997: 25: 372-4.


7. Florian Schumann, * 23.01.1981 in Siegburg, evangelisch Berufliche Tätigkeit 08/2009 -heute Assistenzarzt in der Klinik für Innere Medizin am St. Vinzenz Krankenhaus Hanau


8. Members of the ACCP / SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Consensus Con- ference: definitions for sepsis and organ failure and guidelines for the use of in- novative therapies in sepsis. Crit Care Med. 1992: 20: 864-74.


9. Le G, Jr., Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. Journal of the American Medical Association 1993: 270: 2957-63.


10. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985: 13: 818-29.


11. Wunder C, Eichelbronner O, Roewer N. Are IL-6, IL-10 and PCT plasma con- centrations reliable for outcome prediction in severe sepsis? A comparison with APACHE III and SAPS II. Inflamm.Res. 2004: 53: 158-63.


12. Meisner M. Biomarkers of sepsis: clinically useful? Curr.Opin.Crit Care. 2005: 11: 473-80.


13. Igonin AA, Armstrong VW, Shipkova M, Lazareva NB, Kukes VG, Oellerich M. Circulating cytokines as markers of systemic inflammatory response in se- vere community-acquired pneumonia. Clin Biochem. 2004: 37: 204-9.


14. Tschaikowsky K, Hedwig-Geissing M, Schiele A, Bremer F, Schywalsky M, Schuttler J. Coincidence of pro-and anti-inflammatory responses in the early phase of severe sepsis: Longitudinal study of mononuclear histocompatibility leukocyte antigen-DR expression, procalcitonin, C-reactive protein, and changes in T-cell subsets in septic and postoperative patients. Crit Care Med. 2002: 30: 1015-23.


15. Wolk K, Docke W, von B, V, Volk H, Sabat R. Comparison of monocyte func- tions after LPS-or IL-10-induced reorientation: importance in clinical im- munoparalysis. Pathobiology 1999: 67: 253-6.


16. Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Compari- son of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med. 2003: 31: 1737-41.


17. Reinhart K, Brunkhorst F, Bone H, Gerlach H, Grundling M, Kreymann G, Ku- jath P, Marggraf G, Mayer K, Meier-Hellmann A, Peckelsen C, Putensen C, Quintel M, Ragaller M, Rossaint R, Stuber F, Weiler N, Welte T, Werdan K. [Diagnosis and therapy of sepsis: guidelines of the German Sepsis Society Inc. and the German Interdisciplinary Society for Intensive and Emergency Medi- cine]. Anaesthesist 2006: 55 Suppl 1: 43-56.


18. Clec'h C, Ferriere F, Karoubi P, Fosse JP, Cupa M, Hoang P, Cohen Y. Diagnos- tic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med. 2004: 32: 1166-9.


19. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin J. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am.J.Respir.Crit Care Med. 2001: 164: 396-402.


20. Clec'h C, Fosse JP, Karoubi P, Vincent F, Chouahi I, Hamza L, Cupa M, Cohen Y. Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Crit Care Med. 2006: 34: 102-7.


21. Moerer O, Schmid A, Hofmann M, Herklotz A, Reinhart K, Werdan K, Schnei- der H, Burchardi H. Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med. 2002: 28: 1440-6.


22. Selberg O, Hecker H, Martin M, Klos A, Bautsch W, Kohl J. Discrimination of sepsis and systemic inflammatory response syndrome by determination of circu- lating plasma concentrations of procalcitonin, protein complement 3a, and inter- leukin-6. Crit Care Med. 2000: 28: 2793-8.


23. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical de- terminant of survival in human septic shock. Crit Care Med. 2006: 34: 1589-96.


24. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Muller B. Effect of procalcitonin-guided treatment on antibiotic use and out- come in lower respiratory tract infections: cluster-randomised, single-blinded in- tervention trial. Lancet. 2004: 363: 600-7.


25. Brunkhorst FM. [Epidemiology, economy and practice --results of the German study on prevalence by the competence network sepsis (SepNet)]. Anasthesi- ol.Intensivmed.Notfallmed.Schmerzther. 2006: 41: 43-4.


26. Brun-Buisson C, Meshaka P, Pinton P, Vallet B. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med. 2004: 30: 580-8.


27. Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP. High circulat- ing levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Im- munoglobulin Study Group. Am J Med. 1991: 91: 23-9.


28. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High se- rum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993: 341: 515-8.


29. Herzum I EKRHWH. HLA-DR monitoring of septic patients: the preanalytical issue. Clin Chem. 2005: S6: A75.


30. Hoflich C, Volk HD. Immunomodulation in sepsis. Chirurg 2002: 73: 1100-4.


31. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez- Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical anti- biotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003: 31: 2742-51.


32. Karlsson S, Varpula M, Ruokonen E, Pettila V, Parviainen I, la-Kokko TI, Kolho E, Rintala EM. Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med. 2007: 33: 435-43.


33. Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, Thijs LG, Aarden LA. Increased plasma levels of inter- leukin-6 in sepsis. Blood. 1989: 74: 1704-10.


34. Meisner M, Muller V, Khakpour Z, Toegel E, Redl H. Induction of procalcitonin and proinflammatory cytokines in an anhepatic baboon endotoxin shock model. Shock 2003: 19: 187-90.


35. Song M, Kellum JA. Interleukin-6. Crit Care Med. 2005: 33: S463-S465.


36. Perry SE, Mostafa SM, Wenstone R, Shenkin A, McLaughlin PJ. Is low mono- cyte HLA-DR expression helpful to predict outcome in severe sepsis? Intensive Care Med. 2003: 29: 1245-52.


37. Fumeaux T, Pugin J. Is the measurement of monocytes HLA-DR expression useful in patients with sepsis? Intensive Care Med. 2006: 32: 1106-8.


38. St. Martinus-Hospital Olpe (Krankenpflege) Schulbildung 1991 -2000


39. Docke WD, Hoflich C, Davis KA, Rottgers K, Meisel C, Kiefer P, Weber SU, Hedwig-Geissing M, Kreuzfelder E, Tschentscher P, Nebe T, Engel A, Mon- neret G, Spittler A, Schmolke K, Reinke P, Volk HD, Kunz D. Monitoring tem- porary immunodepression by flow cytometric measurement of monocytic HLA- DR expression: a multicenter standardized study. Clin Chem. 2005: 51: 2341-7.


40. Hershman MJ, Cheadle WG, Wellhausen SR, Davidson PF, Polk HC, Jr. Mono- cyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient. Br.J.Surg. 1990: 77: 204-7.


41. Aikawa N, Fujishima S, Endo S, Sekine I, Kogawa K, Yamamoto Y, Kushimoto S, Yukioka H, Kato N, Totsuka K, Kikuchi K, Ikeda T, Ikeda K, Harada K, Sa- tomura S. Multicenter prospective study of procalcitonin as an indicator of sep- sis. J Infect.Chemother. 2005: 11: 152-9.


42. Oberhoffer M, Vogelsang H, Russwurm S, Hartung T, Reinhart K. Outcome prediction by traditional and new markers of inflammation in patients with sep- sis. Clin.Chem.Lab Med. 1999: 37: 363-8.


43. Monneret G, Lepape A, Voirin N, Bohe J, Venet F, Debard AL, Thizy H, Bien- venu J, Gueyffier F, Vanhems P. Persisting low monocyte human leukocyte an- tigen-DR expression predicts mortality in septic shock. Intensive Care Med. 2006: ..


44. Lee YJ, Park CH, Yun JW, Lee YS. Predictive comparisons of procalcitonin (PCT) level, arterial ketone body ratio (AKBR), APACHE III score and multiple organ dysfunction score (MODS) in systemic inflammatory response syndrome (SIRS). Yonsei Med J. 2004: 45: 29-37.


45. Hynninen M, Pettila V, Takkunen O, Orko R, Jansson SE, Kuusela P, Renkonen R, Valtonen M. Predictive value of monocyte histocompatibility leukocyte anti- gen-DR expression and plasma interleukin-4 and -10 levels in critically ill pa- tients with sepsis. Shock 2003: 20: 1-4.


46. Oberhoffer M, Stonans I, Russwurm S, Stonane E, Vogelsang H, Junker U, Jager L, Reinhart K. Procalcitonin expression in human peripheral blood mono- nuclear cells and its modulation by lipopolysaccharides and sepsis-related cyto- kines in vitro. J.Lab Clin Med. 1999: 134: 49-55.


47. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospi- talization and mortality rates for severe sepsis in the United States: A trend analysis from 1993 to 2003*. Crit Care Med. 2007.


48. Moreno RP, Metnitz B, Adler L, Hoechtl A, Bauer P, Metnitz PG. Sepsis mor- tality prediction based on predisposition, infection and response. Intensive Care Med. 2008: 34: 496-504.


49. Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamua M. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory re- sponse syndrome (SIRS)/sepsis. Cytokine 2005: 29: 169-75.


50. American College of Chest Physicians/Society of Critical Care Medicine Con- sensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992: 20: 864-74.


51. Marshall JC, Maier RV, Jimenez M, Dellinger EP. Source control in the man- agement of severe sepsis and septic shock: an evidence-based review. Crit Care Med. 2004: 32: S513-S526.


52. Monneret G, Finck ME, Venet F, Debard AL, Bohe J, Bienvenu J, Lepape A. The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immu- nol.Lett. 2004: 95: 193-8.


53. Rau B, Steinbach G, Baumgart K, Gansauge F, Grunert A, Beger HG. The clini- cal value of procalcitonin in the prediction of infected necrois in acute pancreati- tis. Intensive Care Med. 2000: 26 Suppl 2: S159-S164.


54. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A pro- spective study. Journal of the American Medical Association 1995: 273: 117-23.


55. Budelmann G. [Hugo Schottmuller, 1867-1936. The problem of sepsis]. Inter- nist (Berl) 1969: 10: 92-101.


56. Vincent JL, Moreno R, Takala J, Willatts S, De MA, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996: 22: 707-10.


57. Haveman JW, Muller Kobold AC, Tervaert JW, van den Berg AP, Tulleken JE, Kallenberg CG, The TH. The central role of monocytes in the pathogenesis of sepsis: consequences for immunomonitoring and treatment. Neth.J.Med. 1999: 55: 132-41.


58. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am.J.Respir.Crit Care Med. 2008: 177: 498-505.


59. Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med. 2003: 31: 2332-8.


60. Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, Lamy M. Cytokine serum level during severe sepsis in human IL-6 as a marker of sever- ity. Ann.Surg. 1992: 215: 356-62.


61. Lekkou A, Karakantza M, Mouzaki A, Kalfarentzos F, Gogos CA. Cytokine production and monocyte HLA-DR expression as predictors of outcome for pa- tients with community-acquired severe infections. Clin.Diagn.Lab Immunol. 2004: 11: 161-7.